AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12867205
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment (mean daily dose 50 mg) in specialist clinics
Trial: 9209246
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 mg azithromycin
Trial: 9209246
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of two 250 mg azithromycin capsules
Trial: 8221740
Drug: Gallopamil (GAL)
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (GAL) 50 mg tid
Trial: 8221740
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (AML) 10 mg/daily
Trial: 30717693
Drug: Test &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test & Treat TB intervention with immediate GeneXpert testing; participants received expedited TB treatment initiation, monthly SMS reminders, and non-cash incentives.
Trial: 25483170
Drug: Standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitation program (physical and occupational therapy for 60 min per day, five times a week, for four weeks)
Trial: 23159962
Drug: 6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL bupivacaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL (Group 2)
Trial: 23159962
Drug: 8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL saline (Group 1)
Trial: 12766625
Drug: d-Amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine (0, 5, 10, and 15 mg)
Trial: 3936140
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (200 mg/day for 9 days)
Trial: 28585143
Drug: Single-allergen sublingual
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-allergen sublingual immunotherapy (SLIT) with a single HDM extract
Trial: 28585143
Drug: Multi-allergen subcutaneous
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-allergen subcutaneous immunotherapy (SCIT) with multiple-allergen extracts (HDM and other allergens)
Trial: 20087780
Drug: Robotic tumor-specific
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic tumor-specific rectal surgery (RTSRS)
Trial: 19034219
Drug: ATG-Fresenius (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-Fresenius (9 mg/kg day 0; 3 mg/kg day 1-4)
Trial: 19034219
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg day 0, 14, 28, 42, 56)
Trial: 16598296
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Altastaph/kg
Trial: 12947437
Drug: Filtered coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered coffee 600 ml/day for 4 weeks
Trial: 9100202
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride (50 mg/ml) root treatment for 5 minutes (TTC‐HCl group)
Trial: 9100202
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid root treatment for 3 minutes (CA group)
Trial: 7903034
Drug: Hydroxychloroquine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine and sulphasalazine combination treatment
Trial: 3861844
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral supplements
Trial: 31916533
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment plus respiratory physiotherapy (breathing and airway clearance techniques, exercise training, education for 3 weeks, 3 times per week)
Trial: 31916533
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment (control group)
Trial: 24984177
Drug: Indapamide sustained-release
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide sustained-release 1.5 mg with the addition of perindopril 2-4 mg as required
Trial: 16024091
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment with paroxetine
Trial: 16024091
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment with amitriptyline
Trial: 11105495
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisolone treatment
Trial: 8800303
Drug: Griseofulvin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 1,000 mg once daily
Trial: 6324587
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous administration of hyperimmune cytomegalovirus IgG at a dose of 200 mg/kg on days 25, 50, and 75 following transplant
Trial: 6324587
Drug: Supporting treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supporting treatment control group
Trial: 30920117
Drug: Four-drug metronomic
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug metronomic chemotherapy regimen (oral celecoxib b.i.d., weekly vinblastine, oral cyclophosphamide for three weeks alternating with oral methotrexate for three weeks, with a two-week rest)
Trial: 30920117
Drug: Four-drug metronomic
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug metronomic chemotherapy regimen
Trial: 31156913
Drug: Pharmacist complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist complex intervention (home visit at 1, 3, and 6 months) including medication review, medicines and lifestyle advice, PCI resolution, and supply of individualised patient information.
Trial: 26803316
Drug: Rectal cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal cleansing enemas
Trial: 19880673
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise and risk reduction therapy including educational sessions, a low‐fat diet, and 2 hours of individually prescribed exercise daily.
Trial: 17456521
Drug: Integrated smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated smoking cessation treatment within mental health care
Trial: 15311146
Drug: No CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CPAP therapy (control group)
Trial: 11136492
Drug: Failure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure to use perioperative antibiotics
Trial: 9634157
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group treatment program (3 hours of group treatment, 3 days a week)
Trial: 9634157
Drug: Weekly individual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly individual outpatient counseling
Trial: 9634157
Drug: Weekly individual
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly individual counseling plus one weekly group session
Trial: 9634157
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who remained in treatment longer
Trial: 9634157
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who remained in treatment
Trial: 7608845
Drug: Tetracycline fiber
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline fiber therapy used adjunctively with scaling and root planing (S and RP)
Trial: 3362944
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg ethanol
Trial: 29617491
Drug: Elastic bandage
RxNorm normalized name: elastic bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic bandage and decongestant physical therapy
Trial: 26147818
Drug: DentalVibe Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DentalVibe Injection Comfort System (DV)
Trial: 24105455
Drug: sirolimus (Rapamune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus (Rapamune 2 mg/d) for 14 days
Trial: 14981379
Drug: 800 microg
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 microg of misoprostol with saline solution (group I, 41 women)
Trial: 14981379
Drug: 800 microg
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 microg of misoprostol without saline solution (group II, 39 women)
Trial: 9722720
Drug: Supragingival plaque
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supragingival plaque control and oral hygiene instruction
Trial: 30561562
Drug: Eravacycline 1
RxNorm normalized name: eravacycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline 1 mg/kg every 12 hours for 4-14 days
Trial: 30561562
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g every 8 hours for 4-14 days
Trial: 27716665
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (2 g/day)
Trial: 23382975
Drug: remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (1 µg/ml)
Trial: 23382975
Drug: remifentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (2 µg/ml)
Trial: 21450224
Drug: Multifactorial fall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial fall prevention program (10 twice-weekly, 2-hour sessions with physical and psychological components and a booster session)
Trial: 10831468
Drug: Adverse interpersonal
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse interpersonal events (e.g., death of a loved one)
Trial: 2957348
Drug: Teicoplanin 400
RxNorm normalized name: Teicoplanin 400 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 400 mg intravenous bolus
Trial: 24894344
Drug: Continuous erythropoietin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous erythropoietin receptor activator (CERA)
Trial: 24240244
Drug: 13.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.5 mg levonorgestrel intrauterine contraceptive system
Trial: 24240244
Drug: 19.5 mg
RxNorm normalized name: camphor 19.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.5 mg levonorgestrel intrauterine contraceptive system
Trial: 16506273
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg/d)
Trial: 16506273
Drug: Nateglinide (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (270 mg/d)
Trial: 12672168
Drug: Alcohol received
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol received (0.5 g/kg)
Trial: 12672168
Drug: Alcohol received
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol received (0.5 g/kg) with expectancy of alcohol (2-3 standard drinks)
Trial: 12672168
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alcohol received (0.0 g/kg) and no expectancy
Trial: 11196347
Drug: 360 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/day of anapsos
Trial: 11196347
Drug: 720 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mg/day of anapsos
Trial: 8008366
Drug: Tisacid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid suspension (2.0 g)
Trial: 8008366
Drug: Tisacid tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid tablet (2.0 g)
Trial: 8008366
Drug: Tisacid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid suspension (1.0 g)
Trial: 8008366
Drug: Tisacid tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid tablet (1.0 g)
Trial: 8008366
Drug: Tisacid suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid suspension (0.5 g)
Trial: 8008366
Drug: Tisacid tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisacid tablet (0.5 g)
Trial: 8008366
Drug: Control (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (after administration of tablet or suspension)
Trial: 3051475
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% (2 ml/cm incision) infiltrated into the fascia
Trial: 18290864
Drug: Late hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late hypoglycaemia (nadir of 2.2 mmol/l after 3.5 h of sleep)
Trial: 18290864
Drug: Early hypoglycaemia
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early hypoglycaemia (nadir of 2.2 mmol/l after 1 h of sleep)
Trial: 16817277
Drug: Xuezhikang Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsules
Trial: 11152307
Drug: Captia Select
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captia Select Toxo-G
Trial: 9110115
Drug: Bosentan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (300 mg, intravenous)
Trial: 9110115
Drug: Bosentan (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (0.5 g bid, orally for 14 days)
Trial: 1530434
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 5 micrograms of ISDN
Trial: 1530434
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 15 micrograms of ISDN
Trial: 1530434
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 60 micrograms of ISDN
Trial: 1530434
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 240 micrograms of ISDN
Trial: 1530434
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 1,000 micrograms of ISDN
Trial: 1530434
Drug: Doses greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses greater than 240 micrograms of ISDN
Trial: 4093207
Drug: MONOCLAIR (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MONOCLAIR (40 mg)
Trial: 4093207
Drug: ISMO (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISMO (40 mg)
Trial: 31410465
Drug: low SCFPns
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low SCFPns (12 g SCFPns·steer‐1·d‐1)
Trial: 31410465
Drug: medium SCFPns
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium SCFPns (15 g SCFPns·steer‐1·d‐1)
Trial: 31410465
Drug: high SCFPns
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high SCFPns (18 g SCFPns·steer‐1·d‐1)
Trial: 31410465
Drug: eXPC (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eXPC (7 g XPC·steer‐1·d‐1)
Trial: 31410465
Drug: ANT (330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANT (330 mg monensin + 110 mg tylosin·steer‐1·d‐1)
Trial: 24641778
Drug: evolutionary‐driven cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evolutionary‐driven cognitive therapy (ED‐CT)
Trial: 24641778
Drug: cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive therapy (CT)
Trial: 22196576
Drug: Self-administered relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered relaxation techniques using a CD and booklet
Trial: 18029326
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg + Hydrochlorothiazide 12.5 mg
Trial: 2408179
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy using pen-injectors
Trial: 7332090
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol (Tramal)
Trial: 7332090
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg buprenorphine (Temgesic)
Trial: 19436939
Drug: Clodronate (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (800 mg daily)
Trial: 9129851
Drug: Intravenous enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enalapril
Trial: 3063043
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics (gentamicin 160 mg + metronidazole 400 mg)
Trial: 3063043
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics only (gentamicin 80 mg + metronidazole 500 mg intravenously)
Trial: 17581533
Drug: Fentanyl (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70 kg)
Trial: 17581533
Drug: Buprenorphine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0, 0.125, 0.5, 2, and 8 mg/70 kg)
Trial: 17581533
Drug: Heroin (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin (0, 3.125, 6.25, 12.5, and 25 mg/70 kg)
Trial: 17581533
Drug: Morphine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Trial: 17581533
Drug: Oxycodone (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Trial: 3767146
Drug: Intravenous propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone, 2 mg/kg body weight
Trial: 24681270
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (IIV) without OM-85 BV (n=35)
Trial: 19834330
Drug: Sarpogrelate (oral)
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate (oral) for 12 weeks
Trial: 16117986
Drug: Cefdinir oral
RxNorm normalized name: cefdinir Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir oral suspension 7 mg/kg q12h for 5 days
Trial: 12218521
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg valdecoxib
Trial: 12218521
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg valdecoxib
Trial: 12971029
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg valdecoxib
Trial: 2011701
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sucralfate granulate given four times daily
Trial: 22435877
Drug: Clinical improvement
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical improvement during the first 14 days of study therapy
Trial: 12032720
Drug: naproxen ophthalmic
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen ophthalmic solution
Trial: 7651474
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg of elemental zinc daily)
Trial: 2528425
Drug: Yiqi Yangyin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Yangyin Huoxue prescription
Trial: 1268617
Drug: Methyldopa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (750 or 1000 mg)
Trial: 1268617
Drug: Long-term methyldopa
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term methyldopa treatment
Trial: 1268617
Drug: Methyldopa treatment
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa treatment for two to three weeks